Minimum Manufacturing Costs, National Prices, and Estimated Global Availability of New Repurposed Therapies for Coronavirus Disease 2019

BACKGROUND: Currently, only dexamethasone, tocilizumab, and sarilumab have conclusively been shown to reduce mortality of coronavirus disease 2019 (COVID-19). Safe and effective treatments will need to be both affordable and widely available globally to be used alongside vaccination programs. This a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Junzheng, Levi, Jacob, Ellis, Leah, Hill, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709896/
https://www.ncbi.nlm.nih.gov/pubmed/34988252
http://dx.doi.org/10.1093/ofid/ofab581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709896/
https://www.ncbi.nlm.nih.gov/pubmed/34988252
http://dx.doi.org/10.1093/ofid/ofab581

Ejemplares similares